Roche Holding AG Book Value Per Share 2010-2024 | RHHBY

Current and historical book value per share for Roche Holding AG (RHHBY) from 2010 to 2024. Book value per share can be defined as the amount of equity available to shareholders expressed on a per common share basis. Roche Holding AG book value per share for the three months ending December 31, 2024 was $0.00.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $262.643B $68.726B
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $753.564B 57.78
Johnson & Johnson (JNJ) United States $365.747B 15.12
AbbVie (ABBV) United States $329.946B 18.19
Novo Nordisk (NVO) Denmark $302.281B 20.03
Novartis AG (NVS) Switzerland $254.167B 14.51
Merck (MRK) United States $197.945B 10.12
Pfizer (PFE) United States $137.813B 7.55
Sanofi (SNY) France $118.626B 11.68
Bayer (BAYRY) Germany $30.141B 6.14
Innoviva (INVA) United States $1.280B 13.41